Millennium Management’s Prevail Therapeutics PRVL Stock Holding History
Bought
Maintained
Sold
Millennium Management's PRVL Position: Q1 2021 in Review
Millennium Management sold out of Prevail Therapeutics (PRVL) in Q1 2021, closing a stake of 589,987 shares — an estimated $13.6M sold.
Millennium Management first reported a position in PRVL in Q2 2019 and held it in 6 quarters. The position peaked at $13.6M in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.
- Millennium Management reported no remaining Prevail Therapeutics position as of Q1 2021 after selling out during the quarter.
- Millennium Management sold 589,987 Prevail Therapeutics shares in Q1 2021, an estimated $13.6M.
- Millennium Management first reported a position in Prevail Therapeutics in Q2 2019 and held it in 6 quarters.
- Millennium Management's Prevail Therapeutics position peaked at $13.6M in Q4 2020.
- 0 funds tracked by Wall St. Rank held Prevail Therapeutics as of Q1 2021.
Based on Millennium Management's 13F filing for Q1 2021, filed 17 May 2021.